KPV vs VIP: Peptide Comparison
The table below compares structural features, receptor mechanisms, tissue selectivity, and research applications for KPV and VIP peptides. Amino Acid Length 3 amino acids (tripeptide) 28 amino acids (neuropeptide) KPV is 9× smaller. Greater stability, lower im
This comparison does not assign a generated winner or score.
- The table below compares structural features, receptor mechanisms, tissue selectivity, and research applications for KPV and VIP peptides.
- Amino Acid Length
- 3 amino acids (tripeptide)
- 28 amino acids (neuropeptide)
- KPV is 9× smaller. Greater stability, lower immunogenicity
- Molecular Weight
- ~357 Da
- ~3,326 Da
- Size difference drives pharmacokinetics and delivery route
- Receptor Target
- Receptor-independent (intracellular)
- VPAC1/VPAC2 GPCRs
- KPV bypasses receptor desensitization; VIP allows dose titration
- Primary Mechanism
- Inhibits NF-kappaB translocation
- Elevates cAMP via Gs-protein activation
- Both suppress NF-kappaB but through independent pathways
- Plasma Half-Life
- Minutes (mucosal persistence longer)
- Seconds to minutes (rapid DPP-IV cleavage)
- VIP requires modified analogs for systemic use; KPV stable in mucosa
- Tissue Selectivity
- Mucosal surfaces, mast cells, gut epithelium
- Systemic (immune, pulmonary, GI smooth muscle, CNS)
- KPV = localized; VIP = systemic
- Immune Modulation
- Mast cell stabilization, innate immune suppression
- Th1/Th17 suppression, Treg promotion
- KPV = innate; VIP = adaptive
- Administration Route (Preclinical)
- Oral, topical, intranasal
- Intraperitoneal, intravenous, subcutaneous
- KPV functional via mucosal routes; VIP requires parenteral dosing
- Primary Research Applications
- IBD, allergic dermatitis, mast cell disorders
- Autoimmune disease, pulmonary inflammation, neuroprotection
- Match peptide to immune compartment targeted
- Purity Requirement
- >98% for consistent NF-kappaB inhibition
- >98% (C-terminal amidation critical)
- Both require high purity. Truncated sequences lose activity